PROCYON CORP logo

PROCYON CORP

PCYN
Last price US$0.26
Market cap US$2.1m
12M price change 36.84%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

PROCYON CORP Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. It provides advanced skin and wound care products, including the hydrogel wound dressing products, post op surgical kits, saline wound washes, care lotions, and barrier lotions to promote healing in wound and problematic skin conditions, as well as hand sanitizer under the AMERIGEL brand name. The company also offers Advantagen, a surgical collagen powder that promotes wound closure and decreases the potential for surgical site infection; and rolled gauze wound care kits. In addition, it provides Bioactive Collagen products in the form of power and matrix under the HELIX3 brand name. Further, the company offers wound care products, such as calcium alginate, foam, gauze, and hyrdocolloid dressing products, as well as retention tapes; and wound care kits, which include calcium alginate, collagen matrix, collagen powder, foam, and hydrogel wound care kits under the AMERX brand name, as well as compression garment line products under the EXTREMIT-EASE brand name. It sells its products through distributors to institutional customers, such as hospitals, wound care clinics, nursing homes, home health agencies, physicians, and health care practitioners; and retail customers through direct sales, and internet sales, as well as through independent and retail chain drug stores. The company was incorporated in 1987 and is based in Oldsmar, Florida. Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems in the United States. It provides advanced skin and wound care products, includ Read More

Mavefund brings filings, fundamentals, valuation, price history and news for PROCYON CORP into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed Oct 25, 2024

Quarterly result summary

Latest company-filed earnings material is available for source review.

What changed

  • Review the SEC source filing for the full reported results and management commentary.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

SEC filing Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

No qualified company news in the last 14 days

No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

Earnings Per Share

Score 3.00/5
PROCYON CORP boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Return on Equity

Score 2.22/5
PROCYON CORP exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
PROCYON CORP PCYN US$2.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 3.36/5
PROCYON CORP commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
PROCYON CORP PCYN US$2.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Leverage

Score 2.89/5
PROCYON CORP attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
PROCYON CORP PCYN US$2.1m
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

PROCYON CORP logo

PROCYON CORP

US$0.26

US$2.1m

52.94%

36.84%